FluroTech Ltd. (TEST.V)
| Previous Close | 0.0050 |
| Open | 0.0050 |
| Bid | 0.0050 x 0 |
| Ask | 0.0100 x 0 |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0050 - 0.0600 |
| Volume | |
| Avg. Volume | 31,061 |
| Market Cap | 603,430 |
| Beta (5Y Monthly) | -0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0520 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FluroTech Ltd. Announces Sale of Shares in FluroTest Diagnostic Systems Ltd. and Option Cancellation
CALGARY, Alberta, Jan. 03, 2023 (GLOBE NEWSWIRE) -- FluroTech Ltd. (“FluroTech” or the “Company”) (TSXV: TEST) announces that it has entered into a Share Purchase Agreement (“Agreement”) to sell all of the shares of FluroTest Diagnostic Systems Ltd., a wholly-owned subsidiary of the Company, to an arm’s length individual (the “Purchaser”). The Purchaser has agreed to pay total cash consideration of $1.00 in lawful Canadian currency. The completion of the transaction is effective December 31, 202
- GlobeNewswire
FluroTech Announces Strategic Exit of COVID-19 Pandemic Testing Business
CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”) announces that it has decided to exit the pandemic and emerging disease industry immediately and halt any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”). Due to declining rates of COVID-19 and the establishment of testing protocols by various governmental and commercial bodies, the demand for FluroTech’s PEDDP has signi
- GlobeNewswire
FluroTech Provides Operational Update: Announces Pause on Further Development of its Pandemic and Emerging Disease Defense Platform
CALGARY, Alberta, April 08, 2022 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (the “Company” or “FluroTech”), announces that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to c
